PERMAX (nda019385)- (EQ 0.05MG BASE,EQ 0.25MG BASE,EQ 1MG BASE)

Generic Name	PERGOLIDE MESYLATE	Innovator	VALEANT PHARM INTL
Dosage	EQ 0.05MG BASE,EQ 0.25MG BASE,EQ 1MG BASE
ParaIV Filing	Yes	505(b)2 Filing	No
Last Patent Expiry	2009-Oct-19	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	Permax is indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson’s disease.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	None

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
EQ 0.05MG BASE	**	**	-	-	-
EQ 0.25MG BASE	**	**	-	-	-
EQ 1MG BASE	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
No	0

Manufacturing Details of PERMAX